Loading…
Loading…
RBOT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RBOT and 80,000+ other tickers.
See exactly how RBOT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RBOT and 80,000+ other tickers.
Vicarious Surgical Inc. is dedicated to the development and commercialization of advanced single-incision surgical robotics. Their innovative technology is designed to give surgeons a virtual, immersive presence within the patient's body, facilitating highly precise and minimally invasive operations. The company's primary product, the Vicarious System, is a sophisticated single-incision robot engineered specifically for procedures like ventral hernia repair. Established in 2014, Vicarious Surgical Inc. operates from its corporate headquarters in Waltham, Massachusetts.
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.
WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone.
WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the “OTCQB”).
Waters (NYSE: WAT - Get Free Report) and Vicarious Surgical (NYSE: RBOT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Insider and Institutional Ownership 94.0% of Waters shares are